• Relapsed ovarian cancer: cediranib/olaparib combo extends PFS

    Phase 2 data show effect is driven by subset without a known BRCA mutation.

  • Artificial intelligence predicts treatment response in epithelial ovarian cancer
    Artificial intelligence predicts treatment response in epithelial ovarian cancer

    The novel Radiomic Prognostic Vector has been developed by researchers at Imperial College London and the University of Melbourne.

  • USPSTF: draft supports screening for BRCA risk in primary care

    A positive screen warrants genetic counseling and potential genetic testing.

  • Heavily treated ovarian cancer: avelumab does well in phase 1b JAVELIN

    Responses were irrespective of PD-L1 and BRCA status.

  • Ovarian cysts: observation a safe alternative to surgery in IOTA5

    20% of masses resolve spontaneously within 2 years.

  • Watchful waiting appropriate for most adnexal ovarian masses
    Watchful waiting appropriate for most adnexal ovarian masses

    Results from the International Ovarian Tumor Analysis Phase 5 (IOTA5) study, the largest of its kind to date.

  • Breastfeeding may protect against ovarian cancer for 30+ years

    Breastfeeding for as little as 3 months shows protective effect.

  • Ovarian cancer: niraparib similarly effective in elderly patients

    Post hoc analysis showed similar PFS benefit regardless of age, BRCA mutation.

  • Olaratumab fails to show benefit in platinum-resistant ovarian cancer
    Olaratumab fails to show benefit in platinum-resistant ovarian cancer

    Randomised study of olaratumab plus liposomal doxorubicin in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

  • Recurrent ovarian cancer: cabozantinib fails phase 2 trial

    OS and toxicities were worse vs weekly paclitaxel.

  • Expert Commentary – Ovarian cancer: main improvements in 2018

    PARP inhibitors in recurrent ovarian cancer increase PFS. But if used more and more as first-line therapy, what will we do with PARP inhibitors in later lines?

  • BRCA+ ovarian cancer: heavily treated patients retain chemosensitivity in Spanish study

    Primary PFI, platinum-based CT, and PARP-inhibitors strongly predict outcomes.

  • KEYNOTE-028: pembrolizumab shows efficacy in ovarian cancer

    Active in advanced recurrent disease, with safety profile consistent vs other studies.

  • EOC: 1 in 7 women develop VTE within 6 months of debulking surgery

    Guidelines do not recommend VTE prophylaxis for outpatients.

  • Load more